BioSenic S.A. : Information on the total number of voting rights and shares
03 7월 2023 - 2:00PM
BioSenic S.A. : Information on the total number of voting rights
and shares
REGULATED INFORMATION
Mont-Saint-Guibert, Belgium, July 3rd,
2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and
Paris: BIOS), the innovative company addressing unmet medical needs
in in the areas of innate immunity, inflammation and organ/function
repair, today announces an increase in the total number of voting
rights and shares as a result of the issuance of new shares
following the conversion of convertible bonds (CBs). The following
information is published in accordance with Article 15 of the
Belgian Law of 2 May 2007 on the publication of major shareholdings
in issuers whose shares are admitted to trading on regulated
market.
Total amount of share capital on 31 May 2023 |
EUR 34,000,669 |
Total number of shares with voting rights on 31 May 2023 |
126,508,857 |
Total number of new shares issued between 01 June 2023 and 02 July
2023 |
625,000 |
Total amount of share capital on 02 July 2023 |
EUR 34,050,669 |
Total number of shares with voting rights on 02 July 2023 |
127,133,857 |
Total number of voting rights (denominator) on 02 July 2023 |
127,133,857 |
Total number of attributed warrants |
1,197,554 |
Total number of convertible bonds outstanding |
831 |
Total number of remaining CB commitments |
30 |
Total number of shares with voting rights that can be issued
following the exercise of the attributed warrants and CB
commitments, and the conversion of the convertible bonds |
40,540,765 (2) |
(1)
- 1,197,554 shares could be issued in case all 1,197,554
attributed warrants were exercised.
- 285,714 shares could be issued in case all 800 convertible
bonds outstanding, issued in the private placement on 6 May
2020, were converted into shares based on the predetermined
conversion price of EUR 7.00.
- 39,057,497 shares could be issued in case all 30 CB commitments
remaining and all 31 convertible bonds outstanding of the ABO CB
program signed on 30 May 2022 were exercised and converted into
shares based on the conversion price of EUR 0.0781 (95% of the
Volume-Weighted-Averaged-Price of BioSenics’ shares on 29 June
2023).
About BioSenic
BioSenic is a leading biotech company
specializing in the development of clinical assets issued from:
(i), the allogeneic cell therapy platform ALLOB and (ii) the
Arsenic TriOxide (ATO) platform. Key target indications for the
platforms include Graft versus Host Disease (GvHD), Systemic lupus
erythematosus (SLE), Systemic Sclerosis (SSc) and high-risk tibial
fractures.Following the merger in October 2022, BioSenic combines
the strategic positionings and strengths of Medsenic and Bone
Therapeutics. The merger also enables Biosenic to add to its
innovative cell therapy platform and strong IP for tissue repair
protection with an entirely new arsenal of various
anti-inflammatory and anti-autoimmune formulations using the
immunomodulatory properties of ATO/OATO. BioSenic is based in the
Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium.
Further information is available at http://www.biosenic.com.
About BioSenic technology
platformsBioSenic’s technology is based on two main
platforms:
- The allogeneic cell and gene therapy platform, developed by
BioSenic with differentiated bone marrow sourced Mesenchymal
Stromal Cells (MSCs) that can be stored at the point of use in
hospitals. Its current investigational medicinal product, ALLOB,
represents a unique, proprietary approach to organ repair and
specifically to bone regeneration, by turning undifferentiated
stromal cells from healthy donors into bone-forming cells on the
site of injury after a single local injection. These cells are
produced via a BioSenic's scalable manufacturing process. Following
the CTA approval by regulatory authorities in Europe, BioSenic had
initiated patient recruitment for the Phase IIb clinical trial with
ALLOB in patients with difficult tibial fractures, using its
optimized production process. ALLOB was evaluated in a randomized,
double-blind, placebo-controlled Phase IIb study in patients with
high-risk tibial fractures, using its optimized production process,
after a successful first safety and efficacy study (Phase 1/2a) on
fractured long bones, with late delayed union. The patient
recruitment has been halted late February 2023 with 57 patients and
the new rules permitted for statistical analysis allowed BioSenic
to get the main results of this trial much earlier than anticipated
in the original protocol, by this mid-June 2023. In June 2023,
BioSenic decided to suspend its interventional trial on fracture
healing using ALLOB, following negative results obtained for the
primary endpoint in the exploratory Phase IIb clinical trial with
ALLOB IIb, which focused on safety and treatment timing
efficacy.
- The Arsenic TriOxide (ATO) platform developed by Medsenic. The
immunomodulatory properties of ATO have demonstrated a double basic
effect on cells of the immune system. The first effect is the
increase of the cell oxidative stress in activated B, T or other
cells of the innate/adaptative immune system to the point they will
enter a cell death program (apoptosis) and be eliminated. The
second effect is potent immunomodulatory properties on several
pro-inflammatory cytokines involved in inflammatory or autoimmune
cell pathways. One direct application is its use in onco-immunology
to treat GvHD (Graft-versus-Host Disease) in its chronic,
established stage. GvHD is one of the most common and clinically
significant complications affecting long-term survival of
allogeneic hematopoietic stem cell transplantation (allo-SCT). GvHD
is primarily mediated by the transplanted immune system that can
lead to severe multiorgan damage. Medsenic had been successful in a
Phase II trial with its intravenous formulation, allowing arsenic
trioxide to be granted an orphan drug designation status by FDA and
EMA and is heading towards an international Phase III confirmatory
study, with a new, IP protected, oral (OATO) formulation. Moderate
to Severe forms of Systemic Lupus erythematosus (SLE) is another
selected target, using the same oral formulation. ATO has shown
good safety and significant clinical efficacy on several affected
organs (skin, mucosae and the gastro-intestinal tract) in a Phase
IIa study.
Systemic Sclerosis is also, part of the clinical
pipeline of BioSenic. Preclinical studies on pertinent animal
models are positive. This gives good grounds to launch a Phase II
clinical protocol for this serious disease that badly affects skin,
lungs or vascularization, and with no actual current effective
treatment.
In addition, BioSenic is developing a
next-generation, off-the-shelf, enhanced viscosupplement, JTA,
consisting of a unique combination of plasma proteins, hyaluronic
acid (a natural component of synovial fluid in the knee) and a
third active component. JTA or some derivatives intend to provide
added lubrication and protection to the cartilage of the arthritic
joint and to alleviate osteoarthritic pain (OA) and inflammation.
In March 2023, after the identification of new OA subtypes,
BioSenic delivered a new post-hoc analysis of its Phase III JTA-004
trial on knee OA with positive action on the most severely affected
patient population. This new post-hoc analysis drastically changes
the therapeutic profile of the combined components and allows for
better patient targeting in new clinical developments. The company,
which does not intend to allocate R&D resources to support the
clinical development of JTA-004 itself will focus its R&D
activities on the development of its autoimmune (ATO) platform.
For further information, please
contact:
BioSenic SAFrançois Rieger, PhD,
Chief Executive OfficerTel: +33 (0)671 73 31
59investorrelations@biosenic.com
International Media Enquiries:IB
CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20
8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Investor Enquiries:Seitosei
ActifinGhislaine GasparettoTel: +33 (0)1 56 88 11
22ggasparetto@actifin.fr
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company or, as
appropriate, the Company directors’ current expectations and
projections about future events. By their nature, forward-looking
statements involve a number of risks, uncertainties and assumptions
that could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, competition and technology, can cause actual
events, performance or results to differ significantly from any
anticipated development. Forward looking statements contained in
this press release regarding past trends or activities should not
be taken as a representation that such trends or activities will
continue in the future. As a result, the Company expressly
disclaims any obligation or undertaking to release any update or
revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither the Company nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
Biosenic (EU:BIOS)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Biosenic (EU:BIOS)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024